Breast Cancer Research

official impact factor 5.79

Open Access Highly Access Research article

Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis

Yiyu Zou1, Wen-Bin Tsai2, Chien-Jui Cheng3, Chiun Hsu4, Young M Chung2, Pao-Chen Li2, Sue-Hwa Lin5 and Mickey CT Hu2*

Author Affiliations

1 Department of Medicine, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York, New York 10467, USA

2 Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Holcombe Blvd, Houston, Texas 77030, USA

3 Department of Pathology, Taipei Medical University and Hospital, Wu Shin Street, Taipei, 11049, Taiwan

4 Department of Oncology, National Taiwan University Hospital, Chung-Shan South Road, Taipei, 100, Taiwan

5 Molecular Pathology, University of Texas MD Anderson Cancer Center, Holcombe Blvd, Houston, Texas 77030, USA

For all author emails, please log on.

Breast Cancer Research 2008, 10:R21 doi:10.1186/bcr1872

Published: 29 February 2008

Abstract

Introduction

Estrogen receptors (ERs) play key roles in breast cancer development and influence treatment outcome in breast cancer patients. Identification of molecules that regulate ER function may facilitate development of breast cancer treatment strategies. The forkhead box class O (FOXO) transcription factor FOXO3a has been suggested to function as a tumor suppressor in breast cancer. Using protein-protein interaction screening, we found that FOXO3a interacted with ER-α and ER-β proteins in the human breast carcinoma cell line MCF-7, suggesting that there exists a crosstalk between the FOXO3a and ER signaling pathways in estrogen-dependent breast cancer cells.

Methods

The interaction between FOXO3a and ER was investigated by using co-immunoprecipitation and immunoblotting assays. Inhibition of ER-α and ER-β transactivation activity by FOXO was determined by luciferase reporter assays. Cell proliferation in culture was evaluated by counting cell numbers. Tumorigenesis was assessed in athymic mice that were injected with MCF-7 cell lines over-expressing FOXO3a. Protein expression levels of cyclin-dependent kinase inhibitors, cyclins, ERs, FOXM1, and the proteins encoded by ER-regulated genes in MCF-7 cell lines and breast tumors were examined by immunoblotting analysis and immunohistochemical staining.

Results

We found that FOXO3a interacted with ER-α and ER-β proteins and inhibited 17β-estradiol (E2)-dependent, ER-regulated transcriptional activities. Consistent with these observations, expression of FOXO3a in the ER-positive MCF-7 cells decreased the expression of several ER-regulated genes, some of which play important roles in cell proliferation. Moreover, we found that FOXO3a upregulated the expression of the cyclin-dependent kinase inhibitors p21Cip1, p27Kip1, and p57Kip2. These findings suggest that FOXO3a induces cell growth arrest to effect tumor suppression. FOXO3a repressed the growth and survival of MCF-7 cells in cell culture. In an orthotopic breast cancer xenograft model in athymic mice, over-expression of FOXO3a in MCF-7 cells suppressed their E2-induced tumorigenesis, whereas knockdown of FOXO3a in MCF-7 resulted in the E2-independent growth.

Conclusion

Functional interaction between FOXO3a and ER plays a critical role in suppressing estrogen-dependent breast cancer cell growth and tumorigenesis in vivo. This suggests that agents that activate FOXO3a may be novel therapeutic agents that can inhibit and prevent tumor proliferation and development in breast cancer.